Cannabis Shows Promise in Alleviating Symptoms for Patients with Advanced Pancreatic Cancer
KEY FINDINGS:
A recent randomized clinical trial involving 32 patients suffering from advanced pancreatic cancer has revealed that early access to medical cannabis can significantly diminish the burdensome symptoms experienced by these individuals, all while presenting only minimal side effects.
RESEARCH APPROACH:
* Those diagnosed with pancreatic cancer frequently endure moderate to severe symptoms such as pain, nausea, insomnia, and a loss of appetite, which greatly detract from their quality of life. Current treatment methods often fall short in effectively managing these issues. Preliminary studies have indicated that medical cannabis could be beneficial in alleviating several cancer-related symptoms; however, high-quality research has been limited due to various regulatory challenges.
* To explore this further, researchers executed a pilot study that was randomized and controlled with a waitlist approach, enrolling 32 patients (median age of 71) who had recently been diagnosed with either locally advanced or metastatic pancreatic adenocarcinoma and were experiencing at least one significant symptom.
* Participants were randomly divided into two groups: one receiving early access to cannabis (0-8 weeks) and another experiencing a delayed access (9-16 weeks). The Minnesota Medical Cannabis Program facilitated the cannabis intervention, providing both products and educational support on how to utilize them properly.
* The primary focus of the study was to assess feasibility, while secondary objectives included evaluating acceptability, changes in symptom distress, and overall quality of life through exploratory efficacy analyses.
INSIGHTS AND IMPLICATIONS:
* Initially, patients reported a considerable burden from their symptoms, with insomnia affecting 85%, pain impacting 77%, and appetite loss noted by 69%. Notably, 31% of participants were also using opioids for pain management.
* The trial successfully met all its feasibility criteria, showing that 74% of participants met eligibility requirements and 81% adhered to their assigned intervention. Patients who gained early access to cannabis typically obtained their products just three days after initiating chemotherapy, with most opting for tablets or other oral formulations.
* After eight weeks, those in the early cannabis access group showed numerically greater improvements in pain relief (44% vs. 20%; P = .35), appetite enhancement (56% vs. 30%; P = .37), and insomnia reduction (67% vs. 30%; P = .18). Additionally, there was a noted decrease in opioid use among these patients. Interestingly, reports of potential side effects from cannabis, such as dry mouth, dizziness, and difficulties with concentration, were lower in comparison to the waitlist group—possibly due to the authors' guidance to "start low, go slow" when using cannabis.
* During the study, patients made an average of two visits to a cannabis dispensary, with most expressing that the process of using cannabis was straightforward and practical.
CONCLUSION AND FUTURE DIRECTIONS:
The authors concluded that "Early access to medical cannabis was linked with observable improvements in specific symptoms like insomnia, while causing minimal adverse effects.” They emphasized that the design of this research serves as a model for collaboration between researchers and governmental cannabis programs.
"The promising preliminary findings regarding the effectiveness and safety of cannabis in symptom management warrant further investigation," they added.
SOURCE OF STUDY:
This research was spearheaded by Dr. Dylan Zylla, MD, MS, at the HealthPartners Institute, Cancer Research Center in Minneapolis, Minnesota. It was presented on January 9 at the ASCO Gastrointestinal Cancers Symposium 2026 and was simultaneously published in JCO Oncology Practice.
LIMITATIONS OF THE STUDY:
While the trial offered valuable insights, it was relatively small in scale, and the eight-week duration limited the ability to draw conclusions regarding long-term benefits and safety. The findings may not be widely applicable, as the study was conducted in a single state with a predominantly urban and White patient demographic. Variations in state cannabis regulations could also affect the generalizability of the results.
DISCLOSURES:
The study received philanthropic funding from the HealthPartners Cancer Research Center. Cannabis products were supplied by Vireo Health (GreenGoods, Minnesota). Additional disclosures are noted in the original article.
